# Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™

> **NCT00654901** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 881 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Pertussis
- Hepatitis B
- Poliomyelitis
- Haemophilus Influenzae Type B Infection

## Interventions

- **BIOLOGICAL:** DTaP-IPV-Hep B-PRP~T vaccine (Batch 1)
- **BIOLOGICAL:** DTaP-IPV-Hep B-PRP~T vaccine (Batch 2)
- **BIOLOGICAL:** DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)
- **BIOLOGICAL:** Infanrix Hexa™

## Key facts

- **NCT ID:** NCT00654901
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2009-05
- **Final completion:** 2009-07
- **Target enrollment:** 881 (ACTUAL)
- **Last updated:** 2016-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00654901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00654901, "Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00654901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*